A5114374171- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cytokine Signaling Pathways and Interactions
- Immune Cell Function and Interaction
- Radiopharmaceutical Chemistry and Applications
- Immunotherapy and Immune Responses
- PARP inhibition in cancer therapy
- T-cell and B-cell Immunology
- interferon and immune responses
- Ethics in Clinical Research
- Immune Response and Inflammation
- Ferroptosis and cancer prognosis
- Cancer Cells and Metastasis
- Psoriasis: Treatment and Pathogenesis
- BRCA gene mutations in cancer
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Peptidase Inhibition and Analysis
- Genomics and Rare Diseases
- Cancer-related molecular mechanisms research
- Health Literacy and Information Accessibility
- Statistical Methods in Clinical Trials
Prostate Cancer Foundation
2015-2024
John Wiley & Sons (United States)
2018-2019
Hudson Institute
2018-2019
City of Hope
2013-2016
Beckman Research Institute
2013-2016
University of California, Los Angeles
2007-2012
National Jewish Health
2009
University of Colorado Denver
2009
Immune dysfunction develops in patients with many cancer types and may contribute to tumor progression failure of immunotherapy. Mechanisms underlying cancer-associated immune are not fully understood. Efficient IFN signaling is critical lymphocyte function; animals rendered deficient develop at higher rates. We hypothesized that altered be a key mechanism common cancer. To address this, we assessed the functional responses peripheral blood lymphocytes from 3 major cancers: breast cancer,...
Inflammation has increasingly been recognized as a critical component influencing tumor growth. Recent reports have revealed conflicting evidence for the role of Toll-like receptors (TLR) in modulating tumorigenesis. In our study, we implicate TLR3 mediating immune surveillance with increased growth implanted transgenic adenocarcinoma mouse prostate (TRAMP) tumors TLR3(-/-) compared TLR3(+/+) mice. Activation by polyinosinic-polycytidylic acid (polyI:C) leads to induction multiple...
Abstract IL6 is a pleiotropic cytokine with both pro- and anti-inflammatory properties, which acts directly on cancer cells to promote their survival proliferation. Elevated serum levels negatively correlate of patients, generally attributed the direct effects cells. How modulates host immune response in patients unclear. Here, we show signaling peripheral blood T impaired breast associated blunted Th17 differentiation. The mechanism identified involved downregulation gp130 IL6Rα was...
Prostate-specific membrane antigen (PSMA) is a credentialed imaging and therapy (theranostic) target for the detection treatment of prostate cancer. PSMA-targeted PET molecular radiotherapy are promising evolving technologies that will improve outcomes cancer patients. In anticipation this new era in theranostics, article review history PSMA from discovery through early- late-stage clinical trials. Since 1993, Prostate Cancer Foundation has funded critical foundational research established...
TANK-binding kinase-1 (TBK1) and the inducible IkappaB kinase (IKK-i) have recently been shown to activate type I IFN responses elicited by intracellular detection of RNA or DNA from infecting viruses. Detection viral is mediated retinoic acid gene-I melanoma differentiation-associated gene-5 pathways in which TBK1 IKK-i demonstrated play redundant roles activation. In this study, we examined whether such redundancy occurs response challenges examining induction IFNs IFN-mediated signaling...
Hypomethylated CpG oligonucleotides (CpG) are not only potent adjuvants for enhancing adaptive immune responses but may also play a critical role in the development of autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). Here we provide evidence that, addition to dendritic cells, murine B lymphocytes exhibit type I IFN response CpG-B. Unlike cell-mediated induction depended on transcription factor IRF3, similar cells this pathway was independent IRF3...
Androgen deprivation therapy remains the backbone for treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, several treatments, including docetaxel, abiraterone + prednisone, enzalutamide, and apalutamide, have each been shown to demonstrate survival benefit when used upfront along with androgen therapy. However, selection an individual patient a challenge. There is no high level clinical evidence among these choices based on biological drivers disease. August...
The 2023 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, themed "Disrupting Research: Challenge Accepted," was convened at the University of California, Los Angeles, Luskin Conference Center, in CA, from June 22 to 25, 2023.
Introduction The 24th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 5‐7, 2017, at the Omni Shoreham Hotel in Washington, DC. Methods PCF is a scientific conference that specifically focuses on cutting edge research deemed to have significant promise for accelerating advances prostate cancer biology and treatment. Results Themes highlighted this year's meeting included: (i) new understandings disease progression; (ii) mechanisms treatment targets advanced...